The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Diabetes Care
Jay M SosenkoType 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups

Abstract

We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

References

May 31, 2002·The New England Journal of Medicine·UNKNOWN Diabetes Prevention Trial--Type 1 Diabetes Study Group
Mar 27, 2004·Lancet·E A M GaleUNKNOWN European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Apr 19, 2008·Clinical Chemistry·Randie R LittleDaniel T Stein
Oct 1, 2008·Pediatric Diabetes·Jeffrey L MahonUNKNOWN Type 1 Diabetes TrialNet Study Group
Jun 18, 2011·Diabetes Care·Jay M SosenkoUNKNOWN Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups
Jun 8, 2013·Diabetologia·Jeffrey P Krischer, UNKNOWN Type 1 Diabetes TrialNet Study Group

❮ Previous
Next ❯

Citations

May 31, 2018·Current Opinion in Endocrinology, Diabetes, and Obesity·Francesco DottaAlberto Pugliese
Jul 15, 2017·Pediatric Diabetes·Srinath Sanda, UNKNOWN Type 1 Diabetes TrialNet Study Group
Jul 1, 2016·Current Opinion in Endocrinology, Diabetes, and Obesity·Jay M Sosenko
Apr 22, 2021·Endocrine Reviews·Michelle SoCarla J Greenbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.